Verimatrix and TELUS Team Up to Showcase First-of-Its Kind Piracy Protections for New Optik TV at IBC 2023
5.9.2023 18:45:00 EEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, will showcase how Verimatrix Streamkeeper was integrated with the next generation of TELUS’ Optik TV platform to create an advanced, industrial-scale video content delivery platform that uniquely prevents video piracy and keeps valuable entertainment secure at IBC 2023.
TELUS, a world-leading communications technology company, needed to securely deliver premium video content across platforms to millions of Canadian customers. They deployed the Verimatrix Streamkeeper platform, which combines Multi-DRM, advanced anti-piracy protections and analytics in a single scalable solution. This enabled robust security for video on demand (VOD) and live content while optimizing operations. Verimatrix Streamkeeper supports a range of Digital Rights Management (DRMs) and integrations to work across TELUS's delivery network, including set-top boxes, mobile apps, and web streaming. The cloud-based architecture brings efficiency, flexibility, and failover capabilities. Together, Verimatrix and TELUS created an innovative solution with a usage-based model to enable TELUS to confidently distribute premium video experiences today and in the future across its hybrid cloud and on-premises infrastructure.
Geartech Technologies also served as an invaluable partner in the anti-piracy and content protection solution for TELUS. As a distributor and supplier of innovative broadcast solutions, Geartech leveraged their expertise to recommend Verimatrix as the ideal provider to help TELUS ensure protection of their digital assets.
Streamlined integration and a smooth migration path were unwavering requirements for Tom Linder, Director of Content & Consumer DevOps at TELUS:
"We couldn't be more excited to bring our new content delivery solution to market. The team has worked tirelessly to create a truly next-gen content and digital life platform, and we needed a partner who not only shared our vision, but who could listen, adapt, customize and suggest the best path forward. By integrating Verimatrix Streamkeeper's layered approach to security, we have an incredibly powerful and future-proof system that will serve our customers well for years to come."
"It has been exciting to work with TELUS to deploy their next-generation TV and over the top streaming platform,” said Sofia Regojo, Chief Revenue Officer at Verimatrix. “Partnering with fellow innovators such as TELUS means leveraging each other's expertise to push boundaries and achieve more together. It means having open conversations to inspire new ideas and constructively challenging each other to find the best path forward. Most importantly, it means maintaining a shared vision to create solutions that truly make a difference.”
"Piracy continues evolving in smart, unpredictable ways," said Maria Malinkowitsch, Senior Product Manager for Streamkeeper at Verimatrix. "Safeguarding content is no longer enough. Today’s modern solutions must also secure vulnerable edges, at scale, and include real-time cybersecurity countermeasures that won't affect the viewer experience."
The two companies will appear on a panel discussion together at IBC 2023 taking place September 17 in Amsterdam and moderated by Andy Waltenspiel, a broadcast industry veteran. Additionally, an innovation story video will be featured at the Verimatrix IBC booth #1.D81.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905936608/en/
Contact information
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
Verimatrix Media Contacts:
USA
Matthew Zintel, Zintel Public Relations
matthew.zintel@zintelpr.com
Europe
Lara Joseph, Eskenzi PR
lara@eskenzipr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom